TY - JOUR
T1 - Health-Related QOL and Economic Burden of Chronic Pruritus
AU - Whang, Katherine A.
AU - Khanna, Raveena
AU - Williams, Kyle A.
AU - Mahadevan, Varun
AU - Semenov, Yevgeniy
AU - Kwatra, Shawn G.
N1 - Funding Information:
SGK is the recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation and received a grant from Skin of Color Society. This work was supported by a trainee grant from the Health Utilities.
Funding Information:
SGK is the recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation and received a grant from Skin of Color Society. This work was supported by a trainee grant from the Health Utilities. Conceptualization: SGK, YS, KAWh; Data Curation: YS, KAWh; Formal Analysis: YS, KAWh; Methodology: SGK, YS, KAWh; Supervision: SGK, YS; Visualization: YS, SGK, KAWh; Writing - Original Draft Preparation: KAWh; Writing - Review and Editing: KAWh, RK, KAWi, VM, YS, SGK
Publisher Copyright:
© 2021 The Authors
PY - 2021/4
Y1 - 2021/4
N2 - Chronic pruritus (CP) has considerable implications for QOL. However, its impact on health-related QOL and economic burden is not fully characterized. We administered a cross-sectional survey on 132 patients with CP using the Health Utilities Index Mark 3 instrument. Normative data from healthy adults (n = 4,187) were obtained from the Joint Canada/US Survey of Health. Quality-adjusted life-year loss and economic costs were estimated on the basis of Health Utilities Index Mark 3 scores of patients with CP versus controls. Patients with CP had lower overall health performance than the control (0.56 ± 0.03 vs. 0.86 ± 0.003, P < 0.001). In multivariable regression, CP was associated with worse overall health performance (coefficient = −0.30, 95% confidence interval = −0.33 to −0.27), most accentuated in the domains of pain (coefficient = −0.24, confidence interval = −0.28 to −0.21) and emotion (coefficient = −0.11, confidence interval = −0.13 to −0.10). The reduced Health Utilities Index Mark 3 score correlated with 5.5 average lifetime quality-adjusted life-years lost per patient. Using conservative estimates for willingness to pay, the quality-adjusted life-year loss translated to an individual lifetime economic burden of $274,921 and a societal burden of $88.8 billion. CP is associated with significant QOL impairment. The economic burden of CP highlights the necessity for further research into management options.
AB - Chronic pruritus (CP) has considerable implications for QOL. However, its impact on health-related QOL and economic burden is not fully characterized. We administered a cross-sectional survey on 132 patients with CP using the Health Utilities Index Mark 3 instrument. Normative data from healthy adults (n = 4,187) were obtained from the Joint Canada/US Survey of Health. Quality-adjusted life-year loss and economic costs were estimated on the basis of Health Utilities Index Mark 3 scores of patients with CP versus controls. Patients with CP had lower overall health performance than the control (0.56 ± 0.03 vs. 0.86 ± 0.003, P < 0.001). In multivariable regression, CP was associated with worse overall health performance (coefficient = −0.30, 95% confidence interval = −0.33 to −0.27), most accentuated in the domains of pain (coefficient = −0.24, confidence interval = −0.28 to −0.21) and emotion (coefficient = −0.11, confidence interval = −0.13 to −0.10). The reduced Health Utilities Index Mark 3 score correlated with 5.5 average lifetime quality-adjusted life-years lost per patient. Using conservative estimates for willingness to pay, the quality-adjusted life-year loss translated to an individual lifetime economic burden of $274,921 and a societal burden of $88.8 billion. CP is associated with significant QOL impairment. The economic burden of CP highlights the necessity for further research into management options.
UR - http://www.scopus.com/inward/record.url?scp=85096187827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096187827&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2020.08.020
DO - 10.1016/j.jid.2020.08.020
M3 - Article
C2 - 32941916
AN - SCOPUS:85096187827
VL - 141
SP - 754-760.e1
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
IS - 4
ER -